SMC Rejects PI3K Inhibitor for Advanced Breast Cancer Dr Sheena Meredith

https://www.medscape.com/viewarticle/smc-rejects-pi3k-inhibitor-advanced-breast-cancer-2026a10012ag?src= The Scottish Medicines Consortium (SMC) has rejected the use of inavolisib (Itovebi, Roche) within NHS Scotland to treat adults with locally advanced or metastatic breast cancer who have oestrogen receptor-positive disease and a particular gene mutation. The drug is intended to be used in combination with palbociclib and fulvestrant to treat oestrogen receptor-positive, HER2-negative breast cancer with a mutation in the PIK3CA gene and which has recurred during adjuvant endocrine therapy or within 12 months of completing it.